{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:27:52Z","timestamp":1790789272059,"version":"4.1.0"},"reference-count":86,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.prp.2024.155104","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T12:16:15Z","timestamp":1704802575000},"page":"155104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Immunotherapy for lung cancer"],"prefix":"10.1016","volume":"254","author":[{"given":"Girshani","family":"Sathish","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.K.","family":"Monavarshini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keerthi","family":"Sundaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sendilvelan","family":"Subramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gomathi","family":"Kannayiram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prp.2024.155104_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216569","article-title":"Unrevealing the therapeutic benefits of radiotherapy and consolidation immunotherapy using ctDNA-defined tumor clonality in unresectable locally advanced non-small cell lung cancer","volume":"vol. 582","author":"Yang","year":"2024","journal-title":"Cancer Lett"},{"key":"10.1016\/j.prp.2024.155104_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2023.155025","article-title":"Current state of knowledge and challenges for harnessing the power of dendritic cells in cancer immunotherapy","volume":"vol. 253","author":"Shbeer","year":"2024","journal-title":"Pathol Res. Pract."},{"issue":"4","key":"10.1016\/j.prp.2024.155104_bib3","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S1470-2045(15)00614-2","article-title":"Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial","volume":"vol. 17","author":"Kim","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.prp.2024.155104_bib4","first-page":"53","article-title":"Immunotherapy in lung cancer","volume":"vol. 3","author":"Massarelli","year":"2014","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.prp.2024.155104_bib5","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance","volume":"vol. 16","author":"Bagchi","year":"2021","journal-title":"Annu. Rev. Pathol."},{"issue":"5","key":"10.1016\/j.prp.2024.155104_bib6","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1158\/1078-0432.CCR-14-1187","article-title":"Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer","volume":"vol. 21","author":"Anagnostou","year":"2015","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.prp.2024.155104_bib7","first-page":"154","article-title":"The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas","volume":"vol. 26","author":"McCarthy","year":"2006","journal-title":"Iowa Orthop J."},{"issue":"6","key":"10.1016\/j.prp.2024.155104_bib8","first-page":"471","article-title":"Coley\u2019s toxin: historical perspective","volume":"vol. 4","author":"Bickels","year":"2002","journal-title":"Isr. Med. Assoc. J."},{"issue":"1","key":"10.1016\/j.prp.2024.155104_bib9","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1080\/21645515.2020.1771986","article-title":"Efficacy of immune checkpoint inhibitors in different types of melanoma","volume":"vol. 17","author":"Rossi","year":"2021","journal-title":"Hum. Vaccin Immunother"},{"issue":"1","key":"10.1016\/j.prp.2024.155104_bib10","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.0105-2896.2006.00382.x","article-title":"Signals required for programming effector and memory development by CD8+ T cells","volume":"vol. 211","author":"Mescher","year":"2006","journal-title":"Immunol. Rev"},{"issue":"1","key":"10.1016\/j.prp.2024.155104_bib11","doi-asserted-by":"crossref","first-page":"224","DOI":"10.4049\/jimmunol.1301633","article-title":"CD8+ T Cell\u2013Independent Tumor Regression Induced by Fc-OX40L and Therapeutic Vaccination in a Mouse Model of Glioma","volume":"vol. 192","author":"Murphy","year":"2014","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.prp.2024.155104_bib12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41568-018-0081-9","article-title":"The lung microenvironment: an important regulator of tumour growth and metastasis","volume":"vol. 19","author":"Altorki","year":"2019","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.prp.2024.155104_bib13","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"vol. 144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.prp.2024.155104_bib14","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1016\/j.jtcvs.2017.06.062","article-title":"Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma","volume":"vol. 154","author":"Takamochi","year":"2017","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.prp.2024.155104_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.593831","article-title":"Integrating Liquid Biopsy and Radiomics to Monitor Clonal Heterogeneity of EGFR-Positive Non-Small Cell Lung Cancer","volume":"vol. 10","author":"Cucchiara","year":"2020","journal-title":"Front Oncol"},{"issue":"11","key":"10.1016\/j.prp.2024.155104_bib16","doi-asserted-by":"crossref","first-page":"S199","DOI":"10.1016\/j.jtho.2023.09.316","article-title":"P1.09-02 Midkine Dependent Immunosuppressive Environment in Cerebrospinal Fluid May Promote Leptomeningeal Metastases of EGFR mutant NSCLC","volume":"vol. 18","author":"Li","year":"2023","journal-title":"J. Thoracic Oncol."},{"key":"10.1016\/j.prp.2024.155104_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113469","article-title":"A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study)","volume":"vol. 197","author":"Watanabe","year":"2024","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.prp.2024.155104_bib18","first-page":"87","article-title":"Global cancer statistics, 2012","volume":"vol. 65","author":"Torre","year":"2015","journal-title":"CA Cancer J. Clin"},{"issue":"1","key":"10.1016\/j.prp.2024.155104_bib19","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.canep.2009.12.015","article-title":"Unchanging clinico-epidemiological profile of lung cancer in north India over three decades","volume":"vol. 34","author":"Singh","year":"2010","journal-title":"Cancer Epidemiol"},{"issue":"8","key":"10.1016\/j.prp.2024.155104_bib20","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1200\/JCO.2012.45.8703","article-title":"Harnessing the immune system for the treatment of non-small-cell lung cancer","volume":"vol. 31","author":"Brahmer","year":"2013","journal-title":"J. Clin. Oncol"},{"issue":"2","key":"10.1016\/j.prp.2024.155104_bib21","first-page":"74","article-title":"Tumor immune microenvironment characterization and response to anti-PD-1 therapy","volume":"vol. 12","author":"Santarpia","year":"2015","journal-title":"Cancer Biol. Med."},{"issue":"12","key":"10.1016\/j.prp.2024.155104_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: recent progress and potential biomarkers","volume":"vol. 50","author":"Darvin","year":"2018","journal-title":"Exp. Mol. Med"},{"issue":"7","key":"10.1016\/j.prp.2024.155104_bib23","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1634\/theoncologist.12-7-864","article-title":"Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events","volume":"vol. 12","author":"Weber","year":"2007","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.prp.2024.155104_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/cells11030320","article-title":"Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects","volume":"vol. 11","author":"Tang","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.prp.2024.155104_bib25","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2147\/OTT.S4833","article-title":"CTLA-4 blockade: therapeutic potential in cancer treatments","volume":"vol. 3","author":"Tarhini","year":"2010","journal-title":"Onco Targets Ther"},{"issue":"35","key":"10.1016\/j.prp.2024.155104_bib26","doi-asserted-by":"crossref","first-page":"8968","DOI":"10.1200\/JCO.2005.01.109","article-title":"Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206","volume":"vol. 23","author":"Ribas","year":"2005","journal-title":"J. Clin. Oncol"},{"issue":"1","key":"10.1016\/j.prp.2024.155104_bib27","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","article-title":"CTLA-4: a moving target in immunotherapy","volume":"vol. 131","author":"Rowshanravan","year":"2018","journal-title":"Blood"},{"issue":"6257","key":"10.1016\/j.prp.2024.155104_bib28","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","volume":"vol. 350","author":"Van Allen","year":"2015","journal-title":"Science"},{"issue":"254","key":"10.1016\/j.prp.2024.155104_bib29","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008918","article-title":"Anti\u2013CTLA-4 therapy broadens the melanoma-reactive CD8 + T cell response","volume":"vol. 6","author":"Kvistborg","year":"2014","journal-title":"Sci. Transl. Med."},{"issue":"12","key":"10.1016\/j.prp.2024.155104_bib30","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1182\/blood.V96.12.3663","article-title":"Enhanced antitumor immunity by fusion of CTLA-4 to a self tumor antigen.","volume":"vol. 96","author":"Huang","year":"2000","journal-title":"Blood"},{"issue":"32","key":"10.1016\/j.prp.2024.155104_bib31","doi-asserted-by":"crossref","first-page":"5275","DOI":"10.1200\/JCO.2008.17.8954","article-title":"Anti\u2013Cytotoxic T-Lymphocyte Antigen-4 Antibody: The First in an Emerging Class of Immunomodulatory Antibodies for Cancer Treatment","volume":"vol. 26","author":"Fong","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"S1","key":"10.1016\/j.prp.2024.155104_bib32","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1634\/theoncologist.2019-IO-S1-s05","article-title":"PD-1\/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions","volume":"vol. 24","author":"Xia","year":"2019","journal-title":"Oncologist"},{"issue":"14","key":"10.1016\/j.prp.2024.155104_bib33","doi-asserted-by":"crossref","first-page":"8372","DOI":"10.1073\/pnas.1533209100","article-title":"Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma","volume":"vol. 100","author":"Phan","year":"2003","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"4","key":"10.1016\/j.prp.2024.155104_bib34","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","article-title":"PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy","volume":"vol. 14","author":"Patel","year":"2015","journal-title":"Mol. Cancer Ther"},{"issue":"9","key":"10.1016\/j.prp.2024.155104_bib35","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"vol. 8","author":"Wei","year":"2018","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.prp.2024.155104_bib36","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/1758834011431718","article-title":"Ipilimumab: its potential in non-small cell lung cancer","volume":"vol. 4","author":"Tomasini","year":"2012","journal-title":"Ther. Adv. Med. Oncol"},{"issue":"8","key":"10.1016\/j.prp.2024.155104_bib37","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1093\/neuonc\/nov071","article-title":"Programmed death ligand 1 (PD-L1) as an immunotherapy target in patients with glioblastoma: Table 1","volume":"vol. 17","author":"Vlahovic","year":"2015","journal-title":"Neuro Oncol"},{"issue":"2","key":"10.1016\/j.prp.2024.155104_bib38","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1053\/j.seminoncol.2017.06.007","article-title":"Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable","volume":"vol. 44","author":"Prasad","year":"2017","journal-title":"Semin. Oncol"},{"issue":"2","key":"10.1016\/j.prp.2024.155104_bib39","doi-asserted-by":"crossref","DOI":"10.1038\/nrclinonc.2014.221","article-title":"PD-1\u2013PD-L1 axis: efficient checkpoint blockade against cancer","volume":"vol. 12","author":"Errico","year":"2015","journal-title":"Nat. Rev. Clin. Oncol"},{"issue":"2","key":"10.1016\/j.prp.2024.155104_bib40","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/1758834014567470","article-title":"Nivolumab in NSCLC: latest evidence and clinical potential","volume":"vol. 7","author":"Sundar","year":"2015","journal-title":"Ther. Adv. Med. Oncol"},{"issue":"5","key":"10.1016\/j.prp.2024.155104_bib41","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.ccell.2018.04.001","article-title":"Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer","volume":"vol. 33","author":"Hellmann","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.prp.2024.155104_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109199","article-title":"Effect and biomarker of Nivolumab for non\u2013small-cell lung cancer","volume":"vol. 117","author":"Wang","year":"2019","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.prp.2024.155104_bib43","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/ijc.33415","article-title":"Targeting CTLA-4 in cancer: Is it the ideal companion for PD-1 blockade immunotherapy combinations?","volume":"vol. 149","author":"De Silva","year":"2021","journal-title":"Int. J. Cancer"},{"issue":"24","key":"10.1016\/j.prp.2024.155104_bib44","doi-asserted-by":"crossref","first-page":"6259","DOI":"10.3390\/cancers13246259","article-title":"Identification of Potential Prognostic and Predictive Immunological Biomarkers in Patients with Stage I and Stage III Non-Small Cell Lung Cancer (NSCLC): A Prospective Exploratory Study","volume":"vol. 13","author":"Vaes","year":"2021","journal-title":"Cancers ((Basel))"},{"key":"10.1016\/j.prp.2024.155104_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/CCI.19.00046","article-title":"Machine-Learning and Stochastic Tumor Growth Models for Predicting Outcomes in Patients With Advanced Non-Small-Cell Lung Cancer","volume":"vol. 3","author":"Siah","year":"2019","journal-title":"JCO Clin. Cancer Inform"},{"key":"10.1016\/j.prp.2024.155104_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106214","article-title":"Predictive effect of PD-L1 expression for immune checkpoint inhibitor (PD-1\/PD-L1 inhibitors) treatment for non-small cell lung cancer: A meta-analysis","volume":"vol. 80","author":"Zhang","year":"2020","journal-title":"Int. Immunopharmacol"},{"issue":"11","key":"10.1016\/j.prp.2024.155104_bib47","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/j.jtho.2016.06.006","article-title":"Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma","volume":"vol. 11","author":"Takada","year":"2016","journal-title":"J. Thor. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2024.155104_bib48","article-title":"Predictive biomarkers and mechanisms underlying resistance to PD1\/PD-L1 blockade cancer immunotherapy","volume":"vol. 19","author":"Ren","year":"2020","journal-title":"Mol. Cancer"},{"issue":"7","key":"10.1016\/j.prp.2024.155104_bib49","article-title":"Harnessing liquid biopsies to guide immune checkpoint inhibitor therapy","volume":"vol. 14","author":"Fatima","year":"2022","journal-title":"Cancers ((Basel))"},{"issue":"5","key":"10.1016\/j.prp.2024.155104_bib50","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1080\/21645515.2019.1571892","article-title":"PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations","volume":"vol. 15","author":"Jiang","year":"2019","journal-title":"Hum. Vaccin Immunother"},{"issue":"2","key":"10.1016\/j.prp.2024.155104_bib51","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/sj.onc.1210910","article-title":"TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours","volume":"vol. 27","author":"Conroy","year":"2008","journal-title":"Oncogene"},{"issue":"11_Supplement","key":"10.1016\/j.prp.2024.155104_bib52","doi-asserted-by":"crossref","DOI":"10.1158\/2326-6066.IMM2016-A124","article-title":"Abstract A124: Protumoral effects of TLR7 in lung tumors","volume":"vol. 4","author":"Dajon","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"10.1016\/j.prp.2024.155104_bib53","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2031699","article-title":"Future prospects for cancer immunotherapy - Strategies for ineffective cancers","volume":"vol. 18","author":"Wada","year":"2022","journal-title":"Hum. Vaccin Immunother"},{"issue":"8","key":"10.1016\/j.prp.2024.155104_bib54","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1158\/2326-6066.CIR-14-0110","article-title":"Vaccines for Cancer Prevention: A Practical and Feasible Approach to the Cancer Epidemic","volume":"vol. 2","author":"Finn","year":"2014","journal-title":"Cancer Immunol. Res"},{"issue":"10","key":"10.1016\/j.prp.2024.155104_bib55","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/s00262-008-0536-z","article-title":"Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines","volume":"vol. 57","author":"de Gruijl","year":"2008","journal-title":"Cancer Immunol. Immunother."},{"issue":"6","key":"10.1016\/j.prp.2024.155104_bib56","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1586\/14760584.2014.911093","article-title":"Various ways to improve whole cancer cell vaccines","volume":"vol. 13","author":"Cicchelero","year":"2014","journal-title":"Expert. Rev. Vaccines"},{"issue":"6","key":"10.1016\/j.prp.2024.155104_bib57","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1586\/14760584.2014.911093","article-title":"Various ways to improve whole cancer cell vaccines","volume":"vol. 13","author":"Cicchelero","year":"2014","journal-title":"Expert. Rev. Vaccines"},{"issue":"5","key":"10.1016\/j.prp.2024.155104_bib58","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3810\/pgm.2009.09.2067","article-title":"Developing a vaccine for non-small-cell lung cancer. Commentary","volume":"vol. 121","author":"Santos","year":"2009","journal-title":"Postgrad Med"},{"issue":"3","key":"10.1016\/j.prp.2024.155104_bib59","doi-asserted-by":"crossref","first-page":"342","DOI":"10.4149\/302_151001N511","article-title":"A new hope: the immunotherapy in small cell lung cancer","volume":"vol. 63","author":"Li","year":"2016","journal-title":"Neoplasma"},{"issue":"6","key":"10.1016\/j.prp.2024.155104_bib60","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2217\/imt.15.29","article-title":"MAGE-A3: an immunogenic target used in clinical practice","volume":"vol. 7","author":"Esfandiary","year":"2015","journal-title":"Immunotherapy"},{"issue":"8","key":"10.1016\/j.prp.2024.155104_bib61","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s00262-014-1547-6","article-title":"Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy","volume":"vol. 63","author":"Smith","year":"2014","journal-title":"Cancer Immunol. Immunother"},{"issue":"5","key":"10.1016\/j.prp.2024.155104_bib62","doi-asserted-by":"crossref","first-page":"791","DOI":"10.4161\/onci.19863","article-title":"TG4010","volume":"vol. 1","author":"Limacher","year":"2012","journal-title":"Oncoimmunology"},{"issue":"9","key":"10.1016\/j.prp.2024.155104_bib63","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1517\/14712598.2015.1073709","article-title":"Belagenpumatucel-L for the treatment of non-small cell lung cancer","volume":"vol. 15","author":"Rijavec","year":"2015","journal-title":"Expert. Opin. Biol. Ther"},{"issue":"2 Suppl 2","key":"10.1016\/j.prp.2024.155104_bib64","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jaci.2009.12.980","article-title":"Overview of the immune response","volume":"vol. 125","author":"Chaplin","year":"2010","journal-title":"J. Allergy Clin. Immunol"},{"issue":"5","key":"10.1016\/j.prp.2024.155104_bib65","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S1044-579X(03)00024-5","article-title":"HLA-G and IL-10 expression in human cancer--different stories with the same message.","volume":"vol. 13","author":"Urosevic","year":"2003","journal-title":"Semin. Cancer Biol"},{"issue":"11_Supplement","key":"10.1016\/j.prp.2024.155104_bib66","doi-asserted-by":"crossref","DOI":"10.1158\/2326-6066.IMM2016-A001","article-title":"Abstract A001: Tumor-specific mutant antigens in cancer immunotherapy","volume":"vol. 4","author":"Gubin","year":"2016","journal-title":"Cancer Immunol. Res."},{"issue":"10","key":"10.1016\/j.prp.2024.155104_bib67","article-title":"Limitations of Immunotherapy in Cancer","volume":"vol. 14","author":"Gupta","year":"2022","journal-title":"Cureus"},{"issue":"3","key":"10.1016\/j.prp.2024.155104_bib68","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/14737159.2022.2049244","article-title":"Predictive biomarkers of response to immune checkpoint inhibitors in hepatocellular carcinoma","volume":"vol. 22","author":"Muhammed","year":"2022","journal-title":"Expert. Rev. Mol. Diagn"},{"key":"10.1016\/j.prp.2024.155104_bib69","doi-asserted-by":"crossref","DOI":"10.1177\/1758835918764628","article-title":"Clinical assessment of immune-related adverse events","volume":"vol. 10","author":"Sosa","year":"2018","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"8","key":"10.1016\/j.prp.2024.155104_bib70","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1586\/14737159.2015.1063420","article-title":"Current and future molecular diagnostics in non-small-cell lung cancer","volume":"vol. 15","author":"Li","year":"2015","journal-title":"Expert. Rev. Mol. Diagn."},{"issue":"1","key":"10.1016\/j.prp.2024.155104_bib71","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1186\/s13256-021-02926-y","article-title":"Patterns of immunotherapy-induced pneumonitis in patients with non-small-cell lung cancer: a case series","volume":"vol. 15","author":"Picard","year":"2021","journal-title":"J. Med. Case Rep."},{"issue":"1","key":"10.1016\/j.prp.2024.155104_bib72","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s40364-021-00306-8","article-title":"Imaging biomarkers for evaluating tumor response: RECIST and beyond","volume":"vol. 9","author":"Ko","year":"2021","journal-title":"Biomark Res"},{"issue":"2","key":"10.1016\/j.prp.2024.155104_bib73","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003302","article-title":"Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival","volume":"vol. 10","author":"Manitz","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.prp.2024.155104_bib74","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"vol. 45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.prp.2024.155104_bib75","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"vol. 18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prp.2024.155104_bib76","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejca.2017.10.017","article-title":"Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria","volume":"vol. 88","author":"Tazdait","year":"2018","journal-title":"Eur. J. Cancer"},{"issue":"10","key":"10.1016\/j.prp.2024.155104_bib77","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1158\/1078-0432.CCR-12-2935","article-title":"The clinical viewpoint: definitions, limitations of RECIST, practical considerations of measurement","volume":"vol. 19","author":"Villaruz","year":"2013","journal-title":"Clin. Cancer Res"},{"issue":"9","key":"10.1016\/j.prp.2024.155104_bib78","doi-asserted-by":"crossref","first-page":"7781","DOI":"10.3390\/ijms24097781","article-title":"Machine Learning Models for the Identification of Prognostic and Predictive Cancer Biomarkers: A Systematic Review","volume":"vol. 24","author":"Al-Tashi","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2024.155104_bib79","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.764189","article-title":"Response Evaluation and Survival Prediction Following PD-1 Inhibitor in Patients With Advanced Hepatocellular Carcinoma: Comparison of the RECIST 1.1, iRECIST, and mRECIST Criteria","volume":"vol. 11","author":"Zhou","year":"2021","journal-title":"Front. Oncol"},{"issue":"1","key":"10.1016\/j.prp.2024.155104_bib80","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12943-018-0804-2","article-title":"Kinase-targeted cancer therapies: progress, challenges and future directions","volume":"vol. 17","author":"Bhullar","year":"2018","journal-title":"Mol. Cancer"},{"issue":"3","key":"10.1016\/j.prp.2024.155104_bib81","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3390\/cancers12030731","article-title":"Tyrosine kinase inhibitors in cancer: breakthrough and challenges of targeted therapy","volume":"vol. 12","author":"Pottier","year":"2020","journal-title":"Cancers ((Basel))"},{"issue":"Pt 2","key":"10.1016\/j.prp.2024.155104_bib82","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.semcancer.2022.08.002","article-title":"Artificial intelligence-based prediction of clinical outcome in immunotherapy and targeted therapy of lung cancer","volume":"vol. 86","author":"Yin","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.prp.2024.155104_bib83","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.mri.2020.03.002","article-title":"Radiomic prediction of mutation status based on MR imaging of lung cancer brain metastases","volume":"vol. 69","author":"Chen","year":"2020","journal-title":"Magn. Reson Imaging"},{"issue":"6","key":"10.1016\/j.prp.2024.155104_bib84","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.3390\/cancers14061370","article-title":"Application of Artificial Intelligence in Lung Cancer","volume":"vol. 14","author":"Chiu","year":"2022","journal-title":"Cancers ((Basel))"},{"issue":"2","key":"10.1016\/j.prp.2024.155104_bib85","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jtho.2016.10.007","article-title":"Checkpoint Inhibitors in Metastatic EGFR- Mutated Non\u2013Small Cell Lung Cancer\u2014A Meta-Analysis","volume":"vol. 12","author":"Lee","year":"2017","journal-title":"J. Thoracic Oncol."},{"key":"10.1016\/j.prp.2024.155104_bib86","article-title":"Histopathological images and multi-omics integration predict molecular characteristics and survival in lung adenocarcinoma","volume":"vol. 9","author":"Chen","year":"2021","journal-title":"Front. Cell Dev. Biol."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033824000153?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033824000153?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T07:57:03Z","timestamp":1767167823000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033824000153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":86,"alternative-id":["S0344033824000153"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2024.155104","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy for lung cancer","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2024.155104","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier GmbH. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"155104"}}